Portfolio overlap

BBC / BBMC

Overlap	Shared positions
1.56%	18

Virtus Biotech Clinical Trials ETF

Report dates 01/31/2022 | 98.41% NAV

Overlap / BBC 9.15%

JPMorgan BetaBuilders U.S. Mid Cap Equity ETF

Report dates 01/31/2022 | 99.48% NAV

Overlap / BBMC 1.56%

Largest shared positions

Security	BBC	BBMC	Overlap
Novavax Inc	0.38%	0.22%	0.22%
Intellia Therapeutics Inc	0.56%	0.21%	0.21%
MIRATI THERAPEUTICS INC	0.59%	0.19%	0.19%

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

History





4 matched portfolio dates from 04/30/2020 to 01/31/2022. Both filings use the same portfolio date. The minimum matched share of net assets is 98.41%. The filing dates are 53–60 days after the portfolio dates. This is filing lag. The archive does not establish an exact intraday release time.

Largest changes

04/30/2021 / 01/31/2022 +0.08 pp

Security	Overlap 04/30/2021	Overlap 01/31/2022	Change (pp)
Novavax Inc	0.00%	0.22%	+0.22
Intellia Therapeutics Inc	0.00%	0.21%	+0.21
Fate Therapeutics Inc	0.00%	0.11%	+0.11
CRISPR Therapeutics AG	0.25%	0.14%	-0.11
ChemoCentryx, Inc.	0.07%	0.00%	-0.07
All other shared classes			-0.28

Sources and methodology

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

nport-common-equity-v1

Report dates	Weight (%)	Classes	BBC · SEC	BBMC · SEC
01/31/2022	1.56%	18	0001752724-22-072459	0001752724-22-072505
04/30/2021	1.48%	13	0001752724-21-133410	0001752724-21-136038
07/31/2020	0.73%	6	0001752724-20-199028	0001752724-20-192352
04/30/2020	1.39%	5	0001752724-20-125829	0001718745-20-000189